Follistatin 344 vs IGF-1 LR3
A side-by-side research comparison of Follistatin 344 and IGF-1 LR3 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Follistatin 344 | IGF-1 LR3 |
|---|---|---|
| Full name | Follistatin 344 (FST-344) | Insulin-like Growth Factor-1 Long R3 |
| Category | Muscle Growth | Muscle Growth |
| Status | Research compound | Research compound |
| Mechanism | Binds myostatin and activin A with high affinity, preventing ActRIIB receptor activation. Removes the brake on muscle growth allowing uninhibited satellite cell proliferation. | Activates IGF-1R while evading IGFBP sequestration. Triggers PI3K/Akt/mTOR for protein synthesis, satellite cell proliferation, and amino acid uptake into muscle. |
| Molecular weight | 36,000 Da | 9,111 Da |
| Half-life | 2-4 hours | 20-30 hours (vs 15 min native) |
| Bioavailability | Moderate (SubQ) | High (SubQ/IM) |
| Typical dose | 100-200 mcg | 20-50 mcg |
| Frequency | Daily for 10-30 days | Daily (post-workout) |
| Route | Subcutaneous | Subcutaneous or intramuscular injection |
Follistatin 344 reported benefits
- Significant muscle growth
- Myostatin inhibition
- Increased strength
- Activin neutralization
- Enhanced recovery
IGF-1 LR3 reported benefits
- Potent anabolic effects
- Hyperplasia (new muscle cells)
- Extended half-life
- Enhanced recovery
- Improved nutrient partitioning
- Satellite cell activation
Related comparisons
Research and educational reference only. Not medical advice.